NCT00111319: Phase 3 : VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in NDMM
Updated: Jun 13, 2022
Phase 3 VISTA Study
phase III VISTA trial (Velcade As Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and Prednisone)
NCT00111319: Phase 3 : VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma
NCT00111319: Phase 3 : VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma
The primary reason for this study is to determine whether the addition of VELCADE (bortezomib) for injection to standard melphalan/prednisone (MP) therapy improves the time to disease progression (TTP) in subjects with previously untreated multiple myeloma.
Sponsor
Millennium Pharmaceuticals, Inc.
Collaborator
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier: NCT00111319
Official Title: An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects With Previously Untreated Multiple Myeloma
First Posted : May 20, 2005
Click here for details on ClinicalTrials.gov
Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.
Ann Hematol. 2016 Dec
Click here for details
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
J Clin Oncol. 2013 Feb
Click here for details
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
Eur J Haematol. 2011
Click here for details
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
Blood. 2010 Nov
Click here for details
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
N Engl J Med. 2008 Aug
Click here for details
Locations
Multiple Locations
151 centers in 22 countries in Europe, North and South America, and Asia
United States
Spain
Sweden
Germany
Greece
Israel
Czech Republic
Italy
Russia
Poland
Argentina South America
Australia
New Zealand
Belgium
Hungary
Korea
Taiwan
United Kingdom
Ireland